Press Releases Year None20202019201820172016 Sep 02, 2020 Imara to Present at Upcoming Investor Conferences Aug 25, 2020 Imara Receives Orphan Drug Designation from the European Commission for IMR-687 for the Treatment of Sickle Cell Disease Aug 14, 2020 Imara Reports Second Quarter 2020 Financial Results and Business Highlights Aug 13, 2020 Imara Announces First Patient Dosed in Ardent Phase 2b Clinical Trial of IMR-687 in Sickle Cell Disease Aug 07, 2020 Imara to Webcast Conference Call of Second Quarter 2020 Financial Results Jul 30, 2020 Imara Announces IMR-687 Granted Fast Track Designation and Rare Pediatric Disease Designation for Treatment of Beta-Thalassemia Jun 29, 2020 Imara Added to Membership of U.S. Small-Cap Russell 2000® Index Jun 25, 2020 Imara Announces Recipients of Real Impact Grants Program to Support People Affected by Rare Genetic Blood Disorders Jun 24, 2020 Imara Receives Orphan Drug Designation for IMR-687 for Treatment of Beta-thalassemia Jun 12, 2020 Imara Presents Positive Interim Results from Phase 2a Study of IMR-687 in Sickle Cell Disease at the Virtual European Hematology Association Annual Congress Pagination Current page 1 Page 2 Next page next › Last page last » Displaying 1 - 10 of 17
Press Releases Year None20202019201820172016 Sep 02, 2020 Imara to Present at Upcoming Investor Conferences Aug 25, 2020 Imara Receives Orphan Drug Designation from the European Commission for IMR-687 for the Treatment of Sickle Cell Disease Aug 14, 2020 Imara Reports Second Quarter 2020 Financial Results and Business Highlights Aug 13, 2020 Imara Announces First Patient Dosed in Ardent Phase 2b Clinical Trial of IMR-687 in Sickle Cell Disease Aug 07, 2020 Imara to Webcast Conference Call of Second Quarter 2020 Financial Results Jul 30, 2020 Imara Announces IMR-687 Granted Fast Track Designation and Rare Pediatric Disease Designation for Treatment of Beta-Thalassemia Jun 29, 2020 Imara Added to Membership of U.S. Small-Cap Russell 2000® Index Jun 25, 2020 Imara Announces Recipients of Real Impact Grants Program to Support People Affected by Rare Genetic Blood Disorders Jun 24, 2020 Imara Receives Orphan Drug Designation for IMR-687 for Treatment of Beta-thalassemia Jun 12, 2020 Imara Presents Positive Interim Results from Phase 2a Study of IMR-687 in Sickle Cell Disease at the Virtual European Hematology Association Annual Congress Pagination Current page 1 Page 2 Next page next › Last page last » Displaying 1 - 10 of 17
Aug 25, 2020 Imara Receives Orphan Drug Designation from the European Commission for IMR-687 for the Treatment of Sickle Cell Disease
Aug 13, 2020 Imara Announces First Patient Dosed in Ardent Phase 2b Clinical Trial of IMR-687 in Sickle Cell Disease
Jul 30, 2020 Imara Announces IMR-687 Granted Fast Track Designation and Rare Pediatric Disease Designation for Treatment of Beta-Thalassemia
Jun 25, 2020 Imara Announces Recipients of Real Impact Grants Program to Support People Affected by Rare Genetic Blood Disorders
Jun 12, 2020 Imara Presents Positive Interim Results from Phase 2a Study of IMR-687 in Sickle Cell Disease at the Virtual European Hematology Association Annual Congress
